Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease.

ABSTRACT:

Aims

Hyperkalaemia risk precludes optimal renin-angiotensin-aldosterone system inhibitor use in patients with heart failure (HF), particularly those with chronic kidney disease (CKD). Patiromer is a sodium-free, non-absorbed potassium (K⁺ )-binding polymer approved for the treatment of hyperkalaemia. In PEARL-HF, patiromer 25.2 g (fixed dose) prevented hyperkalaemia in HF patients with or without CKD initiating spironolactone. The current study evaluated the effectiveness of a lower starting dose of patiromer (16.4 g/day) followed by individualized titration in preventing hyperkalaemia and hypokalaemia when initiating spironolactone.

Methods and results

This open-label 8-week study enrolled 63 patients with CKD, serum K⁺ 4.3-5.1 mEq/L, and chronic HF, w

SUBMITTER: Pitt B 

PROVIDER: S-EPMC5933966 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature